Related Experiment Video
Updated: Apr 6, 2026
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Adenoviral gene therapy in hepatocellular carcinoma: a review
Iván Lyra-González1, Laura Esther Flores-Fong1, Ignacio González-García2
1Department of Molecular Biology and Genomics, Institute for Molecular Biology in Medicine and Gene Therapy, CUCS, University of Guadalajara, Sierra Mojada #950, 44281, Guadalajara, JAL, Mexico.
Background:
Hepatocellular carcinoma is the third leading cause of cancer death. Single or multiple mutations in genes related to growth control, apoptosis, invasion and metastasis have been determined; so a better understanding of the molecular genetic basis of malignant transformation, tumor progression and host interaction has led to significant progress in the development of new therapeutic agents. The ability of adenovirus vectors to deliver and express genes at high yields in HCC treatment has been demonstrated and well documented over the last few years.
Objective:
To overview and provide an update of what has been accomplished in the field of adenoviral gene therapy and its application in hepatocellular carcinoma treatment.
Methods:
Original articles were searched using Pubmed and other medical databases to get the most representative and actual information to establish the current state of the investigation of Ad vectors in HCC.
Results:
Good results have been accomplished in preclinical models using new Ad vectors and especially AAV vectors, it is important to motivate further clinical trials to corroborate all the experience obtained.
Conclusions:
Ad and AAV must be considered as an opportunity to improve the quality of life and survival of HCC patients.
Insights
Adenovirus (Ad) and adeno-associated virus (AAV) vectors show promise for treating hepatocellular carcinoma (HCC). Further clinical trials are needed to confirm their efficacy in improving patient survival and quality of life.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality.
- Understanding the molecular genetics of HCC progression is crucial for developing new therapies.
- Adenovirus vectors have demonstrated potential for gene delivery in HCC treatment.
Purpose of the Study:
- To review advancements in adenoviral gene therapy for hepatocellular carcinoma.
- To provide an update on the application of adenoviral vectors in HCC treatment.
Main Methods:
- Literature search of original articles using PubMed and other medical databases.
- Focus on representative and current information regarding Ad vectors in HCC research.
Main Results:
- Adenovirus (Ad) and adeno-associated virus (AAV) vectors have shown positive outcomes in preclinical models.
- Encouraging results warrant further clinical trials to validate preclinical findings.
Conclusions:
- Ad and AAV vectors represent a promising therapeutic avenue for HCC.
- These gene therapy vectors offer potential to enhance survival and quality of life for HCC patients.
More Related Videos
09:13Study of Viral Vectors in a Three-dimensional Liver Model Repopulated with the Human Hepatocellular Carcinoma Cell Line HepG2
Published on: October 24, 2016
09:54Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018